Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YH 12852 (Primary) ; Prucalopride
  • Indications Constipation; Irritable bowel syndrome
  • Focus Adverse reactions
  • Sponsors Yuhan
  • Most Recent Events

    • 07 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 14 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Dec 2013 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea; KCT0000881).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top